Oncology

News

MSD, Eisai abandon combination trial in liver cancer

MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.

Oncology

Interview at ESMO 2025 with AstraZeneca's Nancy Ghattas

ESMO25: Following the science to a cure, with Nancy Ghattas

News

As Blenrep returns, GSK adds another ADC to cancer pipeline

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia.

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

News

GSK's Blenrep's back in US, but with a narrower label

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale.

Oncology

Interview at ESMO 2025 with Adrian Jubb and Roberto Vieira from Corcept Therapeutics

MSD, Eisai abandon combination trial in liver cancer

ESMO25: Following the science to a cure, with Nancy Ghattas

As Blenrep returns, GSK adds another ADC to cancer pipeline

Bayer's prostate cancer drug Nubeqa cleared for NHS use

GSK's Blenrep's back in US, but with a narrower label

ESMO25: On helping patients with high unmet need, with Rober...

Roche's IgAN hopeful sefaxersen passes phase 3 test

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks